TABLE 3

Adverse events: study 1

PlaceboRPL554 (6mg)Salbutamol (200 µg)Salbutamol (200 µg)
+
RPL554 (6mg)
Ipratropium (40 µg)Ipratropium (40 µg)
+
RPL554 (6 mg)
Subjects313132313233
Cough4 (12.9)4 (12.9)7 (21.9)5 (16.1)2 (6.3)8 (24.2)
Dyspnoea02 (6.5)2 (6.3)01 (3.1)1 (3.0)
Catheter site bruise001 (3.1)1 (3.2)1 (3.1)1 (3.0)
Dizziness1 (3.2)02 (6.3)01 (3.1)1 (3.0)
Headache1 (3.2)1 (3.2)2 (6.3)000
Oropharyngeal pain3 (9.7)001 (3.2)00
Rash01 (3.2)2 (6.3)002 (6.1)
Confusion01 (3.2)1 (3.1)01 (3.1)1 (3.0)
Back pain002 (6.3)01 (3.1)0
COPD01 (3.2)002 (6.3)0
Diarrhoea1 (3.2)1 (3.2)1 (3.1)000
Chest discomfort1 (3.2)00001 (3.0)
Haematoma1 (3.2)001 (3.2)00
Migraine1 (3.2)001 (3.2)00
Nasopharyngitis0002 (6.5)00

Data are presented as n or n (%). COPD: chronic obstructive pulmonary disease. Treatment emergent adverse events reported by more than one patient are presented. Patients may have experienced the same adverse event following different study treatments.